Polygenic contributions to performance on the Balloon Analogue Risk Task
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply..
Risky decision-making is a common, heritable endophenotype seen across many psychiatric disorders. Its underlying genetic architecture is incompletely explored. We examined behavior in the Balloon Analogue Risk Task (BART), which tests risky decision-making, in two independent samples of European ancestry. One sample (n = 1138) comprised healthy participants and some psychiatric patients (53 schizophrenia, 42 bipolar disorder, 47 ADHD); the other (n = 911) excluded for recent treatment of various psychiatric disorders but not ADHD. Participants provided DNA and performed the BART, indexed by mean adjusted pumps. We constructed a polygenic risk score (PRS) for discovery in each dataset and tested it in the other as replication. Subsequently, a genome-wide MEGA-analysis, combining both samples, tested genetic correlation with risk-taking self-report in the UK Biobank sample and psychiatric phenotypes characterized by risk-taking (ADHD, Bipolar Disorder, Alcohol Use Disorder, prior cannabis use) in the Psychiatric Genomics Consortium. The PRS for BART performance in one dataset predicted task performance in the replication sample (r = 0.13, p = 0.000012, pFDR = 0.000052), as did the reciprocal analysis (r = 0.09, p = 0.0083, pFDR=0.04). Excluding participants with psychiatric diagnoses produced similar results. The MEGA-GWAS identified a single SNP (rs12023073; p = 3.24 × 10-8) near IGSF21, a protein involved in inhibitory brain synapses; replication samples are needed to validate this result. A PRS for self-reported cannabis use (p = 0.00047, pFDR = 0.0053), but not self-reported risk-taking or psychiatric disorder status, predicted behavior on the BART in our MEGA-GWAS sample. The findings reveal polygenic architecture of risky decision-making as measured by the BART and highlight its overlap with cannabis use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Molecular psychiatry - 28(2023), 8 vom: 19. Aug., Seite 3524-3530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nurmi, E L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.11.2023 Date Revised 20.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41380-023-02123-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360821510 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360821510 | ||
| 003 | DE-627 | ||
| 005 | 20240220232147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41380-023-02123-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1300.xml |
| 035 | |a (DE-627)NLM360821510 | ||
| 035 | |a (NLM)37582857 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nurmi, E L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polygenic contributions to performance on the Balloon Analogue Risk Task |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2023 | ||
| 500 | |a Date Revised 20.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. | ||
| 520 | |a Risky decision-making is a common, heritable endophenotype seen across many psychiatric disorders. Its underlying genetic architecture is incompletely explored. We examined behavior in the Balloon Analogue Risk Task (BART), which tests risky decision-making, in two independent samples of European ancestry. One sample (n = 1138) comprised healthy participants and some psychiatric patients (53 schizophrenia, 42 bipolar disorder, 47 ADHD); the other (n = 911) excluded for recent treatment of various psychiatric disorders but not ADHD. Participants provided DNA and performed the BART, indexed by mean adjusted pumps. We constructed a polygenic risk score (PRS) for discovery in each dataset and tested it in the other as replication. Subsequently, a genome-wide MEGA-analysis, combining both samples, tested genetic correlation with risk-taking self-report in the UK Biobank sample and psychiatric phenotypes characterized by risk-taking (ADHD, Bipolar Disorder, Alcohol Use Disorder, prior cannabis use) in the Psychiatric Genomics Consortium. The PRS for BART performance in one dataset predicted task performance in the replication sample (r = 0.13, p = 0.000012, pFDR = 0.000052), as did the reciprocal analysis (r = 0.09, p = 0.0083, pFDR=0.04). Excluding participants with psychiatric diagnoses produced similar results. The MEGA-GWAS identified a single SNP (rs12023073; p = 3.24 × 10-8) near IGSF21, a protein involved in inhibitory brain synapses; replication samples are needed to validate this result. A PRS for self-reported cannabis use (p = 0.00047, pFDR = 0.0053), but not self-reported risk-taking or psychiatric disorder status, predicted behavior on the BART in our MEGA-GWAS sample. The findings reveal polygenic architecture of risky decision-making as measured by the BART and highlight its overlap with cannabis use | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Laughlin, C P |e verfasserin |4 aut | |
| 700 | 1 | |a de Wit, H |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, A A |e verfasserin |4 aut | |
| 700 | 1 | |a MacKillop, J |e verfasserin |4 aut | |
| 700 | 1 | |a Cannon, T D |e verfasserin |4 aut | |
| 700 | 1 | |a Bilder, R M |e verfasserin |4 aut | |
| 700 | 1 | |a Congdon, E |e verfasserin |4 aut | |
| 700 | 1 | |a Sabb, F W |e verfasserin |4 aut | |
| 700 | 1 | |a Seaman, L C |e verfasserin |4 aut | |
| 700 | 1 | |a McElroy, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Libowitz, M R |e verfasserin |4 aut | |
| 700 | 1 | |a Weafer, J |e verfasserin |4 aut | |
| 700 | 1 | |a Gray, J |e verfasserin |4 aut | |
| 700 | 1 | |a Dean, A C |e verfasserin |4 aut | |
| 700 | 1 | |a Hellemann, G S |e verfasserin |4 aut | |
| 700 | 1 | |a London, E D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular psychiatry |d 1997 |g 28(2023), 8 vom: 19. Aug., Seite 3524-3530 |w (DE-627)NLM09062694X |x 1476-5578 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:8 |g day:19 |g month:08 |g pages:3524-3530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41380-023-02123-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 8 |b 19 |c 08 |h 3524-3530 | ||